According to Zhitong Finance App News, Haixiang Pharmaceutical (002099.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 1,023 million yuan, an increase of 10.56% over the previous year; achieved a net loss attributable to shareholders of listed companies of 640.38 million yuan, which changed from profit to loss over the previous year; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 124 million yuan, year-on-year from profit to loss; basic earnings per share -0.04 yuan.

In the first half of 2026, the company closely focused on the annual business goals and solidly promoted various tasks such as R&D, production, sales, registration and quality, and the overall operation remained stable. The company stepped up BD expansion efforts, actively participated in various pharmaceutical and dye exhibitions in the US, Shanghai, Japan, Bangladesh, etc., continued to develop new customers and new projects, and prepare projects for future development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.